Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VNDA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVanda Pharmaceuticals reports Q1 2026 earnings results
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Vanda released first quarter 2026 financial results via press release and held earnings conference call on May 6, 2026. Specific financial figures are contained in the attached press release.
Item 7.01 view on EDGAR → -
low
Company provided standard forward-looking statement disclosures covering commercial products, development pipeline, clinical timelines, and regulatory matters discussed during the earnings call.
Item 7.01 view on EDGAR →
Summary
Vanda Pharmaceuticals announced its first quarter 2026 financial results on May 6, 2026, through a press release and earnings conference call. This is a routine quarterly disclosure that all public companies must make. The 8-K filing itself does not contain the actual financial figures—those details are in the attached press release, which investors should review separately.
For retail shareholders, the key action item is to review the full press release (Exhibit 99.1) and listen to the earnings call replay to understand the company's Q1 performance, revenue trends for its commercial products, and any updates on its development pipeline. Pay particular attention to management's commentary on product sales trajectories and any changes to clinical trial timelines or regulatory milestones, as these will drive near-term stock performance.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 6, 2026, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2026 (the “Earnings Call”).
Vanda disclosed its first quarter 2026 financial results through a press release and earnings call on May 6, 2026. The actual financial figures are contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body text.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Various statements to be made during the Earnings Call are “forward-looking statements” under the securities laws, including, but not limited to, statements regarding Vanda’s commercial products, plans and opportunities, as well as statements about Vanda’s products in development and the related clinical development and regulatory timelines and commercial potential for such products.
The company provided standard legal disclosure that statements made during the earnings call about commercial products, development pipeline, clinical timelines, and commercial potential are forward-looking and subject to risks and uncertainties. This is routine boilerplate language required for earnings communications.
Event · Item 9.01 — Financial Statements and Exhibits
Vanda Pharmaceuticals filed an 8-K attaching a press release dated May 6, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press release of Vanda Pharmaceuticals Inc. dated May 6, 2026.
The 8-K references an attached press release dated May 6, 2026, but does not disclose the content or subject matter of the release within the filing body itself. The actual materiality depends on the press release content, which is not provided in this excerpt.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify